Abstract
Despite years of investigation, breast cancer remains a major cause of death worldwide. Phage display is a powerful molecular method in which peptide and protein libraries can be displayed via genetic fusions on the surface of phages. This approach has tremendous potential for biomedical applications and has already facilitated the discovery of specific antibodies, specific antigens, and peptides with potential roles in the diagnosis and treatment of malignancies including breast cancer. In this review, we discuss the new and the latest advancements in the applications of the phage display technique in the provision of immune therapeutics for breast cancer.
Keywords: Bacteriophage, phage display, breast cancer, immune therapeutics, peptide library, vaccine.
Current Pharmaceutical Design
Title:Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer
Volume: 24 Issue: 11
Author(s): Atefeh Arab, Rezvan Yazdian Robati, Jessica Nicastro, Roderick Slavcev and Javad Behravan*
Affiliation:
- School of Pharmacy, University of Waterloo, 200 University Ave, Waterloo,Canada
Keywords: Bacteriophage, phage display, breast cancer, immune therapeutics, peptide library, vaccine.
Abstract: Despite years of investigation, breast cancer remains a major cause of death worldwide. Phage display is a powerful molecular method in which peptide and protein libraries can be displayed via genetic fusions on the surface of phages. This approach has tremendous potential for biomedical applications and has already facilitated the discovery of specific antibodies, specific antigens, and peptides with potential roles in the diagnosis and treatment of malignancies including breast cancer. In this review, we discuss the new and the latest advancements in the applications of the phage display technique in the provision of immune therapeutics for breast cancer.
Export Options
About this article
Cite this article as:
Arab Atefeh , Robati Yazdian Rezvan, Nicastro Jessica, Slavcev Roderick and Behravan Javad *, Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer, Current Pharmaceutical Design 2018; 24 (11) . https://dx.doi.org/10.2174/1381612824666180327152117
DOI https://dx.doi.org/10.2174/1381612824666180327152117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD
Current Drug Targets Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges
Current Drug Targets Characterization of Molecular Alterations of BRCA1/2: Analysis and Interpretation Guidelines
Current Women`s Health Reviews Erythropoiesis Stimulating Agents and Anaemia of End-Stage Renal Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Erratum
Current Proteomics Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Current Cancer Therapy Reviews Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Current Drug Targets TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Best Practices and Emerging Trends for Market Access to Personalised Medicine in the US and EU: Learnings for Global Developed and Emerging Markets
Current Pharmacogenomics and Personalized Medicine 4-aryl/heteroaryl-4H-fused Pyrans as Anti-proliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Strategies for Targeting Lentiviral Vectors
Current Gene Therapy MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer
Current Topics in Medicinal Chemistry Quercetin as a Systemic Chemopreventative Agent: Structural and Functional Mechanisms
Mini-Reviews in Medicinal Chemistry Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells
Current Cancer Therapy Reviews Preparation of Water-Soluble Albumin Loaded Paclitaxil Nanoparticles Using Emulsion-Solvent Evaporation Technique
Current Bioactive Compounds Targeting Molecular Imaging of Breast Cancer by Radioimmunodetection Method in Nuclear Medicine
Current Molecular Imaging (Discontinued) Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences